查看购物车
  • Traditional Chinese
  • English
到 2030 年北美生物分析测试服务市场预测 - 区域分析 - 按服务分类；疾病适应症；和最终用户
市场调查报告书
商品编码
1463674

到 2030 年北美生物分析测试服务市场预测 - 区域分析 - 按服务分类；疾病适应症；和最终用户

North America Bioanalytical Testing Services Market Forecast to 2030 - Regional Analysis - by Services ; Disease Indication ; and End User
出版日期: | 出版商: The Insight Partners | 英文 110 Pages | 订单完成后即时交付

价格

2022年北美生物分析测试服务市值为17.9803亿美元，预计2030年将达到39.7142亿美元；预计2022年至2030年CAGR为10.4%。

製药公司不断增加的研发活动外包推动了北美生物分析测试服务市场

製药公司将非其内部结构核心的研发活动外包。外包杂项活动使他们能够有效地专注于其内部核心能力，从而使药物开发过程更好、更具成本效益。此外，外包製造活动以及研发可以缩短週转时间，增加他们的专业知识，并消除大量资本投资的需要，从而使他们受益。根据 BioPlan Associates 对生物製药产能和生产的调查，分析测试/生物测定是 2022 年外包最多的服务，其次是毒性测试、验证服务、产品表征等。虽然发展中国家是透过合约製造对生物分析测试服务需求的最大贡献者，但美国仍然是潜在的外包目的地。调查中 39.6% 的非美国受访者更愿意外包给美国设施。因此，外包的做法在全球范围内越来越流行，特别是在发展中国家，从而有利于生物分析测试服务市场的成长。製药公司正在广泛实施品质源自于设计（QbD）概念，这进一步推动製药公司采用外包服务，以提高其生产流程的稳健性，并确保最佳的产品品质和製造生产力。 QbD 得到美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构的支持。多年来，随着 ICH Q9（品质风险管理）、ICH Q8（R2，药品开发）和 ICH Q10（药品品质系统）的发布，这一概念在製药业获得了广泛关注。根据 ICH Q10 指南，分析方法对于药品品质系统至关重要。在製造中实施分析 QbD (AQbD) 可确保产品品质和效能。外包生物分析测试服务可以帮助製药公司避免对分析设备和熟练专业人员的大量投资，从而降低业务风险，特别是当产品处于开发的早期阶段时。由于专业的分析测试服务提供者俱有快速提供优异结果的关键能力，製药公司越来越多地考虑将生物分析测试服务外包给第三方服务供应商，这推动了市场的成长。

北美生物分析测试服务市场概况

北美占据生物分析测试服务市场的最大份额，其中美国、加拿大和墨西哥是该地区市场成长的主要贡献者。製药业的不间断增长、各种疾病发病率的上升对开发新药的需求不断增加、政府医疗保健支出的增加以及为保证药品质量而对外包活动的日益偏好是有利的因素北美生物分析测试服务市场的增长。

北美生物分析测试服务市场收入及 2030 年预测（百万美元）

北美生物分析测试服务市场细分

北美生物分析测试服务市场根据测试类型、疾病适应症、最终用户和国家进行细分。

根据测试类型，北美生物分析测试服务市场分为药物动力学、生物标记、免疫原性、病毒学测试、基于细胞的测定等。 2022 年，基于细胞的检测领域占据最大的市场份额。

根据疾病适应症，北美生物分析测试服务市场分为心血管、神经系统疾病、代谢失调、呼吸系统疾病、自体免疫疾病、肿瘤、性健康、骨骼疾病等。 2022 年，肿瘤学领域占据最大的市场。

根据最终用户，北美生物分析测试服务市场分为製药和生物製药公司、合约研究组织（CRO）、合约开发和製造组织（CDMO）等。 2022 年，製药和生物製药公司领域占据最大的市场份额。

按国家/地区划分，北美生物分析测试服务市场分为美国、加拿大和墨西哥。 2022年，美国在北美生物分析测试服务市场份额中占据主导地位。

SGS SA、康龙化成北京有限公司、Element Materials Technology Group Ltd、CD BioSciences Inc、Charles River Laboratories International Inc、Eurofins Scientific SE、Labcorp Drug Development Inc、Syneos Health Inc、KCAS Bioanalytical and Biomarker Services LLC、ICON Plc 和Intertek Group Plc 是北美生物分析测试服务市场上的一些领先公司。

目录

表中的内容

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美生物分析测试服务市场格局

  • 概述
  • PEST分析
    • 北美 PEST 分析

第 5 章：北美生物分析测试服务市场 - 主要产业动态

  • 主要市场驱动因素：
    • 药厂增加研发活动外包
    • 对生物相似药和生物製剂分析测试的高需求
  • 主要市场限制：
    • 生物分析方法开发与验证的挑战
  • 主要市场机会
    • 医药产业持续成长
  • 未来的趋势
    • 针对新兴罕见疾病的药物发现和开发活动不断增加
  • 影响分析：

第 6 章：生物分析测试服务市场 - 北美市场分析

  • 生物分析测试服务市场收入，2022 - 2030

第 7 章：北美生物分析测试服务市场 - 收入和 2030 年预测 - 按服务

  • 概述
  • 2022 年和 2030 年生物分析测试服务市场收入份额（按服务划分）（%）
  • 药物动力学
  • 生物标誌物
  • 免疫原性
  • 病毒学检测
  • 基于细胞的检测
  • 其他的

第 8 章：北美生物分析测试服务市场 - 2030 年收入和预测 - 按疾病适应症

  • 概述
  • 2022 年和 2030 年按疾病适应症分類的生物分析测试服务市场收入份额 (%)
  • 心血管
  • 神经系统疾病
  • 自体免疫疾病
  • 呼吸疾病
  • 代谢紊乱
  • 肿瘤学
  • 性健康
  • 骨病
  • 其他的

第 9 章：北美生物分析测试服务市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 2022 年和 2030 年生物分析测试服务市场收入份额（按最终用户划分）（%）
  • 製药和生物製药公司
  • 合约研究组织（CRO）
  • 合约开发与製造组织 (CDMO)
  • 其他的

第 10 章：北美生物分析测试服务市场 - 国家分析

  • 我们
  • 加拿大
  • 墨西哥

第 11 章：生物分析测试服务市场产业格局

  • 概述
  • 生物分析测试服务市场的成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第 12 章：公司简介

  • SGS SA
  • Pharmaron Beijing Co Ltd
  • Element Materials Technology Group Ltd
  • CD BioSciences Inc
  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Labcorp Drug Development Inc
  • Syneos Health Inc
  • KCAS Bioanalytical and Biomarker Services LLC
  • ICON Plc
  • Intertek Group Plc

第 13 章：附录

Product Code: BMIRE00029563

The North America bioanalytical testing services market was valued at US$ 1,798.03 million in 2022 and is expected to reach US$ 3,971.42 million by 2030; it is estimated to grow at a CAGR of 10.4% from 2022 to 2030.

Increasing Outsourcing of R&D Activities by Pharmaceutical Companies fuel the North America Bioanalytical Testing Services Market

Pharmaceutical companies outsource research & development activities that are not core to their internal structure. Outsourcing miscellaneous activities allows them to efficiently focus on their internal core competencies for making the drug development process better and more cost effective. Moreover, outsourcing manufacturing activities, along with R&D, benefits them by lowering the turnaround period, adding to their expertise, and eliminating the need for large capital investments. According to the Survey of Biopharmaceutical Manufacturing Capacity and Production by BioPlan Associates, analytical testing/bioassay was the most outsourced service in 2022, followed by toxicity testing, validation services, product characterization, and others. While developing nations are the largest contributors to the demand for bioanalytical testing services through contract manufacturing, the US remains a potential outsourcing destination. 39.6% of non-US respondents in the survey preferred outsourcing to US-based facilities. Thus, the practice of outsourcing is gaining popularity worldwide, especially in developing countries, thereby favoring the growth of the bioanalytical testing services market. Pharmaceutical businesses are widely implementing the quality-by-design (QbD) concept, which is further propelling the adoption of outsourcing services by pharmaceutical companies to increase the robustness of their production processes and ensure optimal product quality and manufacturing productivity. QbD is supported by regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The concept has gained traction in the pharmaceutical industry over the years with the publication of ICH Q9 (Quality Risk Management), ICH Q8 (R2, Pharmaceutical Development), and ICH Q10 (Pharmaceutical Quality System). According to the ICH Q10 guidelines, analytical methods are essential to the pharmaceutical quality system. Analytical QbD (AQbD) implementation in manufacturing ensures product quality and performance. Outsourcing bioanalytical testing services helps pharmaceutical businesses reduce business risks by avoiding major investments in analytical equipment and skilled professionals, especially while the product is in the early phase of development. Due to the availability of specialized analytical testing service providers with crucial competencies to quickly provide excellent results, pharmaceutical companies are increasingly considering outsourcing bioanalytical testing services to third-party service providers, which fuels the market growth.

North America Bioanalytical Testing Services Market Overview

North America holds the largest share of the bioanalytical testing services market, with the US, Canada, and Mexico being the major contributors to the market growth in this region. The uninterrupted growth of the pharmaceuticals industry, the increasing need for developing novel drugs due to an upsurge in the incidences of various diseases, rising healthcare expenditure by governments, and a growing preference for outsourcing activities for the quality assurance of pharmaceutical products are the factors favoring the growth of the bioanalytical testing services market in North America.

North America Bioanalytical Testing Services Market Revenue and Forecast to 2030 (US$ Million)

North America Bioanalytical Testing Services Market Segmentation

The North America bioanalytical testing services market is segmented based on test type, disease indication, end user, and country.

Based on test type, the North America bioanalytical testing services market is segmented into pharmacokinetics, biomarkers, immunogenicity, virology testing, cell-based assays, and others. The cell-based assays segment held the largest market share in 2022.

Based on disease indication, the North America bioanalytical testing services market is segmented into cardiovascular, neurological disorders, metabolic disorders, respiratory diseases, autoimmune disorder, oncology, sexual health, bone disease, and others. The oncology segment held the largest market share in 2022.

Based on end user, the North America bioanalytical testing services market is segmented into pharmaceutical and biopharmaceutical companies, contract research organization (CRO), contract development and manufacturing organization (CDMO), and others. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2022.

Based on country, the North America bioanalytical testing services market is segmented into the US, Canada, and Mexico. The US dominated the North America bioanalytical testing services market share in 2022.

SGS SA, Pharmaron Beijing Co Ltd, Element Materials Technology Group Ltd, CD BioSciences Inc, Charles River Laboratories International Inc, Eurofins Scientific SE, Labcorp Drug Development Inc, Syneos Health Inc, KCAS Bioanalytical and Biomarker Services LLC, ICON Plc, and Intertek Group Plc are some of the leading companies operating in the North America bioanalytical testing services market.

Table Of Contents

Table of Content

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Bioanalytical Testing Services Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis

5. North America Bioanalytical Testing Services Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Increasing Outsourcing of R&D Activities by Pharmaceutical Companies
    • 5.1.2 High Demand for Analytical Testing of Biosimilars and Biologics
  • 5.2 Key Market Restraints:
    • 5.2.1 Challenges in Development and Validation of Bioanalytical Methods
  • 5.3 Key Market Opportunities
    • 5.3.1 Uninterrupted Growth of Pharmaceuticals Industry
  • 5.4 Future Trends
    • 5.4.1 Rising Drug Discovery and Development Activities for Emerging and Rare Diseases
  • 5.5 Impact Analysis:

6. Bioanalytical Testing Services Market - North America Market Analysis

  • 6.1 Bioanalytical Testing Services Market Revenue (US$ Mn), 2022 - 2030

7. North America Bioanalytical Testing Services Market - Revenue and Forecast to 2030 - by Services

  • 7.1 Overview
  • 7.2 Bioanalytical Testing Services Market Revenue Share, by Services 2022 & 2030 (%)
  • 7.3 Pharmacokinetics
    • 7.3.1 Overview
    • 7.3.2 Pharmacokinetics: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Biomarkers
    • 7.4.1 Overview
    • 7.4.2 Biomarkers: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Immunogenicity
    • 7.5.1 Overview
    • 7.5.2 Immunogenicity: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Virology Testing
    • 7.6.1 Overview
    • 7.6.2 Virology Testing: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.6.2.1 In-Vitro Virology Testing
        • 7.6.2.1.1 Overview
      • 7.6.2.2 In-Vitro Virology Testing: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.6.3 In-Vivo Virology Testing
      • 7.6.3.1 Overview
      • 7.6.3.2 In-Vivo Virology Testing: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Cell-Based Assays
    • 7.7.1 Overview
    • 7.7.2 Cell-Based Assays: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.8 Others
    • 7.8.1 Overview
    • 7.8.2 Others: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Bioanalytical Testing Services Market - Revenue and Forecast to 2030 - by Disease Indication

  • 8.1 Overview
  • 8.2 Bioanalytical Testing Services Market Revenue Share, by Disease Indication 2022 & 2030 (%)
  • 8.3 Cardiovascular
    • 8.3.1 Overview
    • 8.3.2 Cardiovascular: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Neurological Diseases
    • 8.4.1 Overview
    • 8.4.2 Neurological Diseases: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Autoimmune Disorders
    • 8.5.1 Overview
    • 8.5.2 Autoimmune Disorders: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Respiratory Diseases
    • 8.6.1 Overview
    • 8.6.2 Respiratory Diseases: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Metabolic Disorders
    • 8.7.1 Overview
    • 8.7.2 Metabolic Disorders: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.8 Oncology
    • 8.8.1 Overview
    • 8.8.2 Oncology: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.9 Sexual Health
    • 8.9.1 Overview
    • 8.9.2 Sexual Health: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.10 Bone Disease
    • 8.10.1 Overview
    • 8.10.2 Bone Disease: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.11 Others
    • 8.11.1 Overview
    • 8.11.2 Others: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Bioanalytical Testing Services Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Bioanalytical Testing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Pharmaceutical and Biopharmaceutical Companies
    • 9.3.1 Overview
    • 9.3.2 Pharmaceutical and Biopharmaceutical Companies: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Contract Research Organization (CRO)
    • 9.4.1 Overview
    • 9.4.2 Contract Research Organization (CRO): Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Contract Development and Manufacturing Organization (CDMO)
    • 9.5.1 Overview
    • 9.5.2 Contract Development and Manufacturing Organization (CDMO): Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Bioanalytical Testing Services Market - Country Analysis

  • 10.1 North America Bioanalytical Testing Services Market, Revenue And Forecast To 2030
    • 10.1.1 Overview
      • 10.1.1.1 North America Bioanalytical Testing Services Market, by Country
      • 10.1.1.2 US
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 US Bioanalytical Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.2.3 US Bioanalytical Testing Services Market, by Services
        • 10.1.1.2.3.1 US Bioanalytical Testing Services Market, by Virology Testing
        • 10.1.1.2.4 US Bioanalytical Testing Services Market, by Disease Indication
        • 10.1.1.2.5 US Bioanalytical Testing Services Market, by End User
      • 10.1.1.3 Canada
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 Canada Bioanalytical Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.3.3 Canada Bioanalytical Testing Services Market, by Services
        • 10.1.1.3.3.1 Canada Bioanalytical Testing Services Market, by Virology Testing
        • 10.1.1.3.4 Canada Bioanalytical Testing Services Market, by Disease Indication
        • 10.1.1.3.5 Canada Bioanalytical Testing Services Market, by End User
      • 10.1.1.4 Mexico
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Mexico Bioanalytical Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.4.3 Mexico Bioanalytical Testing Services Market, by Services
        • 10.1.1.4.3.1 Mexico Bioanalytical Testing Services Market, by Virology Testing
        • 10.1.1.4.4 Mexico Bioanalytical Testing Services Market, by Disease Indication
        • 10.1.1.4.5 Mexico Bioanalytical Testing Services Market, by End User

11. Bioanalytical Testing Services Market Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Bioanalytical Testing Services Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 SGS SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pharmaron Beijing Co Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Element Materials Technology Group Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 CD BioSciences Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Charles River Laboratories International Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Eurofins Scientific SE
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Labcorp Drug Development Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Syneos Health Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 KCAS Bioanalytical and Biomarker Services LLC
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 ICON Plc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Intertek Group Plc
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Bioanalytical Testing Services Market Segmentation
  • Table 2. US Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Services
  • Table 3. US Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Virology Testing
  • Table 4. US Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
  • Table 5. US Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - End User
  • Table 6. Canada Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Services
  • Table 7. Canada Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Virology Testing
  • Table 8. Canada Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
  • Table 9. Canada Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - End User
  • Table 10. Mexico Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Services
  • Table 11. Mexico Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Virology Testing
  • Table 12. Mexico Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
  • Table 13. Mexico Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn) - End User
  • Table 14. Recent Inorganic Growth Strategies in the Bioanalytical Testing Services Market
  • Table 15. Recent Organic Growth Strategies in the Bioanalytical Testing Services Market
  • Table 16. Glossary of Terms, North America Bioanalytical Testing Services Market

List Of Figures

  • Figure 1. North America Bioanalytical Testing Services Market Segmentation, By Country
  • Figure 2. North America - PEST Analysis
  • Figure 3. North America Bioanalytical Testing Services Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Bioanalytical Testing Services Market Revenue (US$ Mn), 2022 - 2030
  • Figure 6. North America Bioanalytical Testing Services Market Revenue Share, by Services 2022 & 2030 (%)
  • Figure 7. Pharmacokinetics: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Biomarkers: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Immunogenicity: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Virology Testing: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. In-Vitro Virology Testing: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. In-Vivo Virology Testing: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Cell-Based Assays: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Others: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. North America Bioanalytical Testing Services Market Revenue Share, by Disease Indication 2022 & 2030 (%)
  • Figure 16. Cardiovascular: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Neurological Diseases: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Autoimmune Disorders: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Respiratory Diseases: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Metabolic Disorders: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Oncology: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Sexual Health: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Bone Disease: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America Bioanalytical Testing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 26. Pharmaceutical and Biopharmaceutical Companies: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. Contract Research Organization (CRO): Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Contract Development and Manufacturing Organization (CDMO): Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Others: Bioanalytical Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. North America Bioanalytical Testing Services Market, by Country - Revenue 2022 ($Mn)
  • Figure 31. North America Bioanalytical Testing Services Market, By Key Countries, 2022 And 2030 (%)
  • Figure 32. US Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn)
  • Figure 33. Canada Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn)
  • Figure 34. Mexico Bioanalytical Testing Services Market Revenue And Forecast to 2030 (US$ Mn)
  • Figure 35. Growth Strategies in the Bioanalytical Testing Services Market